Antibodies against chromosomal beta-lactamase

Area of Science:

• Microbiology
• Immunology
• Medical Science

Background:

• Cystic Fibrosis (CF) patients often suffer from chronic Pseudomonas aeruginosa infections.
• Beta-lactamase enzymes produced by P. aeruginosa can confer resistance to antibiotics.
• The role of host immune response to bacterial beta-lactamases in CF pathogenesis is not fully understood.

Purpose of the Study:

• To investigate the presence and significance of serum and sputum antibodies against Pseudomonas aeruginosa chromosomal group 1 beta-lactamase in cystic fibrosis patients.
• To explore the correlation between these antibodies and P. aeruginosa infection status, antibiotic resistance, and clinical outcomes.

Main Methods:

• Development of a murine monoclonal anti-chromosomal beta-lactamase antibody.
• Utilized immunoblotting technique to detect serum and sputum antibodies.
• Analyzed serum samples from 56 CF patients (cross-sectional) and 18 CF patients (longitudinal).
• Assessed beta-lactamase activity in sputum samples from 14 CF patients with chronic infection.

Main Results:

• All CF patients with chronic P. aeruginosa infection (CF + P) had detectable serum anti-beta-lactamase IgG antibodies.
• No antibodies were found in CF patients without or with intermittent P. aeruginosa infection.
• Antibodies were present after antibiotic treatment and correlated with beta-lactam-resistant P. aeruginosa strains.
• Beta-lactamase antibodies were found in 10 out of 14 sputum samples, with varying levels of beta-lactamase activity observed.

Conclusions:

• The presence of anti-beta-lactamase antibodies in CF patients with chronic P. aeruginosa infection is significant.
• These antibodies may play a dual role: potentially aiding in defense against infection while also possibly contributing to lung damage via immune complex formation and hyperimmune reactions.